G1 Therapeutics shares are trading higher after the company and Deimos Biosciences announced a licensing agreement for lerociclib for radioprotective uses.
Portfolio Pulse from Benzinga Newsdesk
G1 Therapeutics shares are trading higher following the announcement of a licensing agreement with Deimos Biosciences for the radioprotective uses of lerociclib.
May 22, 2024 | 10:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
G1 Therapeutics shares are trading higher after the company announced a licensing agreement with Deimos Biosciences for the radioprotective uses of lerociclib.
The licensing agreement with Deimos Biosciences for lerociclib's radioprotective uses is a significant development for G1 Therapeutics, likely boosting investor confidence and driving the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100